Objective To investigate the effect of sulfuraphane (SFN) on proliferation of glioma stem cell line SWO-38, and its mechanism threreof. Methods Cell proliferation of SWO-38 treated with SFN was measured by cell prolifera?tion assay. Clone formation experiment, tumor sphere formation experiment and Western blotting method were applied to de?tect the ability of cell clone formation and tumor sphere formation, and the expression of stemness relative genes, such asβ-catenin, Oct4, Sox-2 and c-Myc. The effects of SFN and/or miR-124 inhibitor (miR-124i) on the expression of stemness rel?ative genes were compared. Changes of miRNAs (miRNA-9, 21, 221, 124, 128 and 181) induced by SFN were measured by real time quantity PCR. Results SFN suppressed the proliferation of SWO-38 cells in a dose-dependent manner, in which IC50 was (26.41±2.13)μmol/L. SFN also decreased the ability of forming cell clone and tumor sphere, as well as the expres?sion of stemness relative genes (β-catenin, Oct4, Sox-2 and c-Myc) in a dose-dependent manner. At the same time, SFN led to the change in many miRNAs, during which SFN increased the transcription of miR-124 (-5.9-fold) and miR-128 (-2.6-fold), and decreased the transcription of miR-9, miR-21 and miR-221. Compared to the blank control, the expression levels ofβ-catenin, Oct4, and Sox-2 were significantly increased in miR-124i group. On the other hand, the expressions of above genes were also higher in combined group, which was treated with miR-124i and SFN than those in SFN group, but lower than those of miR-124i group. Conclusion SFN can efficiently inhibit the proliferation of giloma stem cells in SWO-38 cell line through miR-124/(β-catenin/Sox-2/Oct4) signaling pathway.

OBJECTIVE:To discuss the countermeasure on the quality improvement of the drug clinical trials in our hospital based on the discovery of key links of the quality of clinical trials. METHODS:Quality results of 14 drug clinical trials in 10 ma-jors from the drug clinical trial institute in our hospital in 2014 were investigated. Referring to the grading and classifying methods of the inspection problems in European Medicines Agency,the key links of occurring problems were analyzed,and the effects of interventions for key links were evaluated. RESULTS:In 2014,totally 125 important and general problems were found,in which, the numbers of problems occurred in case report form filling,informed consent of subjects,enrolling and screening of subjects,in-vestigational products management accounted for 79.20%. The above 4 links were the key links affecting quality of drug clinical tri-als. According to strengthening the training about relevant knowledge of the researchers,improving system and standard operation procedures management,enhancing link quality control,introducing project clinical research coordinator,developing centralized drug management and other interventions,the total numbers of found important and general problems in 2015 and 2016 were 68 and 59,respectively. Compared with 2014,the differences were statistically significant(P<0.05). The numbers of found important problems in 2015 and 2016 were 7 and 4,respectively. Compared with 2014(4 important problems),the differences were not sta-tistically significant (P>0.05). There were no severe problems during 2014-2016. After interventions,numbers of occurring prob-lems in majors with less complex drug clinical trial had obviously declined in 2016. Compared with 2014,the differences were sta-tistically significant (P<0.05). While the major with relatively high complexity of drug clinical trial had no obvious decline in 2016. Compared with 2014,the differences were not statistically significant(P>0.05). CONCLUSIONS:Controlling the key links in drug clinical trial process can obviously reduce the occurrence of general problems while has little effect on the occurrence of im-portant problems. It is different for different majors in undertaking drug clinical trial projects,so as the links and degree of occur-ring problems. It should be distinguished in quality control checking.

Adult ; Age Factors ; Aged ; Cause of Death ; trends ; China ; Female ; Humans ; Infant ; Male ; Middle Aged ; Neoplasms ; mortality